source
- J&J reports 40% Q2 sales jump for Spravato as psychedelic rivals loomJohnson & Johnson said its depression nasal spray Spravato generated $584 million in worldwide revenue in the second quarter, a 40% increase from a year earlier. The company highlighted the drug as…
- Stakeholders urge FDA to create drug-repurposing framework that avoids disincentives and stays within authorityStakeholders, including patients and healthcare industry groups, told the FDA that repurposing existing drugs offers significant opportunities for new treatments. They warned that any new repurpos…